Table 3.
Overall survival in patients with and without RUX
| PB 0% blasts | PB 1-3% blasts | PB 4% blasts | PB 5-19% blasts | |||||
|---|---|---|---|---|---|---|---|---|
| ALL pts | N | OS (range) | N | OS (range) | N | OS (range) | N | OS (range) |
| Total | 700 | 64 (55-73) | 436 | 48 (43-53) | 29 | 22 (11-33) | 151 | 19 (11-27) |
| RUX | 268 | 81 (61-101) | 190 | 63 (51-75) | 11 | 27 (11-43) | 54 | 47 (23-71) |
| No RUX | 432 | 58 (50-66) | 246 | 40 (30-50) | 18 | 15 (6-24) | 97 | 15 (11-19) |
| HR (95% CI), p-value* | 0.72 (0.56-0.91), 0.01 | 0.64 (0.44-0.93), <0.001 | 0.91 (0.10-0.96), 0.03 | 0.57 (0.37-0.87), 0.007 | ||||
| PMF | N | OS (range) | N | OS (range) | N | OS (range) | N | OS (range) |
| Total | 499 | 59 (51-67) | 300 | 46 (39-53) | 26 | 27 (16-38) | 99 | 22 (14-30) |
| RUX | 183 | 66 (41-91) | 123 | 49 (44-54) | 9 | 27 (17-37) | 39 | 26 (9-43) |
| No RUX | 316 | 55 (46-64) | 177 | 34 (20-48) | 17 | 15 (6-24) | 60 | 14 (7-21) |
| HR (95% CI), p-value* | 1.29 (0.97-1.72), 0.08 | 1.41 (1.04-1.90), 0.02 | 3.2 (0.9-11.4), 0.05 | 1.55 (0.94-2.58), 0.08 | ||||
*
HR (95% CI) and p value between with and without RUX patients within blast groups, RUX-ruxolitinib